A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy

• Published in: Annals of hematology Vol. 90; no. 2; pp. 185 - 192
• Main Authors: Niitsu, Nozomi, Tamaru, Jun-ichi, Yoshino, Tadashi, Nakamura, Naoya, Nakamura, Shigeo, Ohshima, Kohichi, Nakamine, Hirokazu, Okamoto, Masataka
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.02.2011; Springer Nature B.V
• Subjects: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived - therapeutic use; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor - metabolism; Bleomycin - therapeutic use; Cyclophosphamide - therapeutic use; Disease Progression; Disease-Free Survival; Doxorubicin - therapeutic use; Etoposide - therapeutic use; Hematology; Humans; Immunophenotyping; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse - diagnosis; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - metabolism; Lymphoma, Large B-Cell, Diffuse - physiopathology; Male; Medicine; Medicine & Public Health; Middle Aged; NM23 Nucleoside Diphosphate Kinases - metabolism; Oncology; Original Article; Prednisolone - therapeutic use; Prognosis; Rituximab; Vincristine - therapeutic use; Young Adult; Rituximab; BCL2; nm23; Diffuse large B-cell lymphoma
• ISSN: 0939-5555; 1432-0584; 1432-0584
• DOI: 10.1007/s00277-010-1060-8

In our previous study on nm23-H1 expression with diffuse large B-cell lymphoma (DLBCL), we found that patients with positive nm23-H1 had significantly poorer prognosis than patients with negative nm23-H1. We examined whether nm23-H1 is a prognostic factor of DLBCL in the rituximab era. The subjects were 101 DLBCL patients who underwent R-CyclOBEAP (rituximab, cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, and prednisolone) therapy and in whom markers could be analyzed. We evaluated CD5, CD10, BCL2, BCL6, MUM1, and nm23-H1 expression by immunohistochemistry. Ninety-four DLBCL patients who underwent CyclOBEAP therapy were assumed as historical controls. Among DLBCL patients who underwent CyclOBEAP therapy, BCL2 positivity, MUM1 positivity, non-germinal center B-cell (non-GCB), and nm23-H1 positivity were associated with significantly shorter overall survival (OS) and progression-free survival (PFS). On the other hand, among DLBCL patients who underwent R-CyclOBEAP therapy, the 5-year OS rates of the nm23-H1-positive DLBCL ( n  = 32) and nm23-H1-negative DLBCL groups ( n  = 69) were 65% and 97%, respectively ( p  = 0.001), with 5-year PFS rates of 51% and 89%, respectively ( p  = 0.001). In the rituximab era, BCL2, MUM1, and non-GCB were not prognostic factors. We demonstrated that among patients with DLBCL who underwent R-CyclOBEAP therapy, patients with nm23-H1 expression had a significantly poorer prognosis than patients without nm23-H1 expression. These results suggest an important role for nm23-H1 in malignant progression and a potential therapeutic target for DLBCL.